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SUMMARY
Highly active anti-retroviral therapy (HAART) is associated with reduction in the morbidity and
mortality of patients with advanced HIV-1 disease. The ability of such treatment to improve immune
responses against HIV-1 and opportunistic pathogens is variable and limited. Addition of cytokine
immunotherapy to this treatment may improve immune responses. IL-2 with or without granulocyte-
macrophage colony-stimulating factor (GM-CSF) was administered to HIV-1þ individuals receiving
HAART with undetectable viral loads, and CD4 counts < 100 cells/ml. In one patient presenting with
Mycobacterium avium complex (MAC) infection, we evaluated the effect of cytokine immunotherapy
on lymphocyte phenotype; plasma viral load; proliferative responses to mitogens, recall and HIV-1
antigens; cytokine production and message in response to non-specific and specific stimuli; and natural
killer (NK) cell activity. Proliferation assays were performed in two similar patients. Before cytokine
immunotherapy the predominant CD8þ population was mainly CD28¹. No proliferation or IL-2
production was seen in response to mitogens, recall or HIV-1 antigens; and no HIV-1 peptide-specific
interferon-gamma (IFN-g)-secreting cells were present. Low levels of IL-4 were detected in response to
antigens to which patients had been exposed, associated with up-regulated expression of costimulatory
molecules influenced by IL-4. Following IL-2 administration, loss of IL-4 was associated with increased
NK cell activity and HIV-1 peptide-specific and non-specific IFN-g-producing cells. Proliferative
responses associated with IL-2 production and responsiveness were only seen after subsequent
concomitant administration of GM-CSF with IL-2. These changes mirrored clinical improvement. An
imbalance of lymphocyte subsets may account for immune unresponsiveness when receiving HAART.
Restoration of responses following immunotherapy suggests a shift towards a lymphocyte profile with
anti-pathogen activity.
Keywords HIV-1 T cell responses anti-retroviral therapy cytokines immune reconstitution
INTRODUCTION
Treatment of HIV-1-infected persons with highly active anti-
retroviral therapy (HAART) may result in remission of opportu-
nistic infections as well as HIV-1-related symptoms. This effect is
not always observed and specific opportunistic infections may
persist or recur [1–4]. Type 1 cytokine-secreting cells synthesize
IL-2 and interferon-gamma (IFN-g), which have anti-viral activity,
and C-C chemokines which may contribute towards CD4þ cell
resistance to HIV-1 infection [5]. Type 2 cytokine-secreting cells
secrete IL-4 and IL-10. These two subsets play a central regulatory
role in HIV-1 infection, and the balance between them may dictate
the final immunological and clinical outcome [6,7]. Previous
studies suggest that a type 2 cytokine environment, often found
in HIV-1 disease, has an immunosuppressive anti-proliferative
effect [8,9]. An atypical/anergic subset of the CD8þ, CD28¹,
CD57þ, CD38þ cells in HIV-1-infected patients may also sub-
stantiate the immunosuppressed state [10–12]. HAART treatment
of chronic HIV-1 infection results in a gradual increase in non-
specific CD4þ T cell proliferative responses, but increases in HIV-
1-specific CD4þ T lymphocyte proliferation have not been
observed [13–16].
We investigated the immunological response to IL-2 and/or
granulocyte-macrophage colony-stimulating factor (GM-CSF) used
as salvage therapy in conjunction with HAART in HIV-1-infected
patients, presenting with complications such as treatment-resistant
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Mycobacterium avium complex (MAC) and little immune recon-
stitution despite virologically suppressive HAART. We performed
flow cytometry, proliferation assays, cytokine production and
message assessment by ELISPOT assays, bioassays and reverse
transcriptase-polymerase chain reaction (RT-PCR), to assess
alterations in cell-mediated immunity and the relationship with
clinical outcome. Our findings suggest that the combination of
HAART and immunotherapy reversed a type 2-like immunosup-
pressive state, decreasing IL-4 levels and inducing HIV-1 peptide-
specific IFN-g-secreting cells. Non-specific natural killer (NK)
responses were also enhanced. HIV-1-specific proliferative
responses, accompanied by IL-2 production and up-regulated
expression of IL-2-specific mRNA, were noted only upon con-
comitant administration of IL-2 and GM-CSF. Further studies of
such immunomodulators in severely immunocompromised
patients are warranted before progressing to formal long-term
randomized controlled trials.
PATIENTS AND METHODS
Patients
Three patients with advanced HIV-1 disease (CD4 counts < 100)
had received HAART for > 12 months (plasma viral load below
detectable levels; with modest effects on CD4 counts). Patient 3
was diagnosed with MAC which was unresponsive to conventional
treatment, although partly responsive to liposomal amikacin. He
had been on HAART for 14 months, with stavudine, lamivudine
and indinavir, which had effectively suppressed plasma viral load
to below detectable levels. However, the rise in CD4 count
remained modest (nadir ¼ 5, peak ¼ 61 cells/ml). IL-2 (Chiron
Therapeutics, Uxbridge, UK) was administered (5 million units
b.d. subcutaneously for 5 days, in three cycles 6 weeks apart).
During the third cycle in addition to IL-2, GM-CSF (Novartis,
Schering-Plough, Camberley, UK) was included (subcutaneous
injection 60 000 U/kg daily). Peripheral blood was taken for
analysis immediately prior to the first IL-2 administration, and 3
weeks after completion of the first, second and third cycles.
Patients 1 and 2 received only IL-2 in addition to HAART. The
patients’ informed consent and Ethics Committee approval were
obtained for the studies described.
HLA typing
HLA haplotypes of patients and donors were assessed by PCR-SSP
[17,18].
Plasma viral RNA assay
Viral load in patient plasma was measured at each time point of
sample collection using the Amplicor HIV-1 Monitor assay (detec-
tion limit < 200 copies/ml; Roche Diagnostic System, Welwyn
Garden City, UK).
Isolation of peripheral blood mononuclear cells and culture con-
ditions
Peripheral blood mononuclear cells (PBMC) were isolated
by density gradient centrifugation and cultured in supplemented
RPMI 1640 medium [19]. All cell lines were cultured in 10% fetal
calf serum (FCS)/RPMI in 25-cm2 flasks (Greiner Laboritechnik,
Dursley, UK) and incubated at 378C.
Antibodies
The following murine MoAbs were used: anti-human CD3, CD4,
CD8, CD16, CD19 (Ortho-Trio; Ortho-Clinical Diagnostics,
Amersham, UK); anti-human CD45RA–FITC, CD45RO–FITC,
CD57–PE and relevant isotype-matched controls (Sigma, Poole,
UK); anti-human CD28–FITC, ab TCR–FITC, gd TCR–PE and
relevant isotype-matched controls (Pharmingen Division, Becton
Dickinson, Oxford UK); anti-human CD1a, CD40, CD80 and
CD86 (Serotec, Oxford, UK); anti-human CD23 and HLA-DR
(Dako, High Wycombe, UK); anti-human CD38 (Sigma) and
anti-human CD95 (Pharmingen).
Flow cytometry
The Cytotron Absolute (Ortho) was used for flow cytometric
analyses of total CD3þ, CD4þ, CD8þ, CD16þ and CD19þ
lymphocytes using whole blood. For further analysis of cell surface
markers, PBMC were stained according to the manufacturer’s
instructions and where relevant, cells were further incubated with
secondary antibody (FITC goat anti-mouse immunoglobulin;
Dako). Detailed phenotypic evaluation was carried out on a Becton
Dickinson FACScalibur and analysed with CellQuest software.
Proliferation assays
PBMC (105/well) were cultured with antigen, mitogen or cytokine
in round-bottomed microtitre plates (Greiner), in 10% AB plasma/
RPMI (200 ml; Sigma). Antigens and mitogens were used as shown
in Table 1. On day 5, 100 ml of supernatant were collected and
stored at ¹208C for subsequent cytokine measurement. Each
well was then pulsed with 1 mCi 3H-methyl thymidine (3H-TdR;
Amersham Int., Aylesbury, UK) and 16 h later cells were harvested
onto glassfibre filtermats (Wallac Oy, Turku, Finland). Prolifera-
tion as measured by 3H-TdR incorporation was evaluated by liquid
scintillation spectroscopy using a 1205 Betaplate counter (Wallac)
[19]. Results are expressed as the mean ct/min for triplicate
cultures, with percentage error of the mean < 15%. Control
wells, for calculation of background activity, contained PBMC
only.
Measurement of IL-2 and IL-4 production
For cytokine assays 50 ml of supernatants, from proliferative
cultures, were transferred in two sets of 96-well round-bottomed
plates as triplicates for measurement of IL-2 and IL-4 using
indicator cell lines CTLL-2 (European Collection of Animal Cell
Culture (ECACC), Salisbury, UK) and CT.h4S (a generous gift of
W. Paul, Bethesda, MD) as described previously [19]. Briefly,
CTLL-2 (103 cells/well) or CT.h4S (5 · 103 cells/well) were
added in 50 ml to give a final 100 ml. After 24 h in culture, wells
were pulsed with 3H-TdR and harvested as described above.
Results are expressed as the mean ct/min for triplicate cultures,
with percentage error of the mean < 15%.
ELISPOT assays
Detection of single-cell IFN-g release was carried out according
to the protocol described by Lalvani et al. [20]. Briefly, 2·5 · 105
cells/well were cultured with appropriate HLA-B35 restricted
peptide (detailed in Fig. 3c) or phytohaemagglutinin (PHA)
at final concentrations of 10 mg/ml in 96-well polyvinylidene
difluoride-backed plates (Millipore, Watford, UK) coated with
anti-IFN-g MoAb (Mabtech, Stockholm, Sweden). Negative con-
trols comprised cells cultured in the presence or absence of
irrelevant peptide. Plates were incubated overnight at 378C, and
IFN-g spot-forming cells (SFC) were detected according to the
manufacturer’s instructions (Mabtech).
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NK assays
K562 target cells (107; ECACC) were labelled with 100 mCi 51Cr at
378C for 1 h, washed, resuspended at 105/ml and 100 ml were
added to each well of a microtitre plate. Effector cells (100 ml)
(uninfected donor or patient PBMC) were added to give effector
to target ratios ranging from 100:1 to 3:1. Each dilution was
carried out in triplicate and two controls (spontaneous and
total release) were included. Specific release of 51Cr from
radiolabelled target cells was assessed as described previously
[19].
RNA preparation and RT-PCR
PBMC, obtained after the IL-2 and GM-CSF cycle in patient 3,
were cultured for 4 days with or without p24, Candida antigen
(CAN) and IL-2, at final concentrations as described in Table 1.
Every 24 h 106 cells were taken for RNA isolation. Total RNA was
extracted using RNA STAT-60 (AMS Biotechnology, Witney,
UK) and treated with RNase-free DNase I (Boehringer, Roche
Diagnostics, Lewes, UK). The RNA sample was then preheated at
658C for 10 min, placed on ice for a further 10 min, and first-strand
cDNA synthesis was obtained using the Bulk First-Strand cDNA
Synthesis kit (Pharmacia, St Albans, UK). After 1 h, the reaction
was stopped by incubation at 908C for 5 min and samples were
cooled on ice. Amplification of IL-2, IL-4 and IL-10 gene-specific
cDNA was performed using primers: IL-2 (upstream 50 primer
50 CATTGCACTAAGTCTTGCACTTGTCA 30 and downstream
30 50CGTTGATATTGCTGATTAAGTCCCTG 30); IL-4 (50
primer 50 CGGCAACTTTGACCACGGACACAAGTGCGATA
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Table 1. Proliferation and cytokine production in response to HIV-1 recombinant antigens, recall antigens, mitogens, and IL-2
ct/min
Proliferation IL-2 production IL-4 production*
Antigen/mitogen B I II B I II B I II
Medium – – – – – – – – –
186 142
Baculovirus-derived – – þþþ – – þþ þþ – –
recombinant p24, 33 733 9253 3476 141
EVA no. 620, 10 mg/ml
Baculovirus-derived – – þ/¹ – – – þ/¹ – –
recombinant gp120, 977 125 334 136
EVA no. 646, 10 mg/ml
E. coli-derived recombinant – – – – – – – – –
nef, EVA no. 650, 10 mg/ml
Influenza A, Central Public – – – – – – – – –
Health Lab (CPHL) 1/40 184
Herpes simplex virus – – þ – – þ/¹ þþ – –
CPHL 1/40 2640 245 3847 138
Varicela/Zoster – – – – – – – – –
CPHL 1/40
Measles CPHL 1/40 – – – – – – – – –
Cytomegalovirus Behring 1/40 – – – – – – – – –
Respiratory syncytial virus, – – – – – – – – –
Behring 1/40
Tetanus toxoid, – – þ/¹ – – – – – –
Evans Medical 1/40 752 128 130
Purified protein derivative, – – þ/¹ – – þ/¹ þ/¹ – –
Sigma 10 mg/ml 1368 840 528 139
Candida albicans – – þþþ – – þþ þþ – –
NIBSC 32 562 14 626 3812 133
Phytohaemagglutinin – – þþ – – þþ – – –
Wellcome 10 mg/ml 19 202 6182
Concanavalin A – – þ/¹ – – – – – –
Sigma 10 mg/ml 810
Pokeweed mitogen – – þþ – – þþ þ/¹ – –
Sigma 10 mg/ml 10 560 3011 474 135
Recombinant IL-2 – – þþþ ND ND ND ND ND ND
Boehringer 100 U/ml 38 860
B, Before IL-2 immunotherapy; I, after IL-2 immunotherapy; II, after IL-2 and granulocyte-macrophage colony-stimulating factor (GM-CSF)
immunotherapy.
*Levels of IL-4 detected correspond to 1 U/ml of IL-4.
–, < 200 ct/min; þ/¹, 200–1500 ct/min; þ, 1500–3000 ct/min; þþ, 3000–20 000 ct/min; þþþ, > 20 000 ct/min. Results are expressed as the mean ct/
min for triplicate cultures, with percentage error of the mean < 15%.
30 and 30 primer 50 ACGTACTCTGGTTGGCTTCCTTCACAG
GACAG 30); and IL-10 (50 primer 50 AAGCTGAGAACCAAG
ACCCAGACATCAAGGCG 30 and 30 primer 50 AGCTATCCC
AGAGCCCCAGATCCGATTTTGG 30) (all Clontech, Basing-
stoke, UK) following the standardized protocol from Clontech.
Samples were submitted to 35 cycles of amplification with the
following cycle profiles: denaturation at 948C for 45 s, annealing at
608C for 45 s, extension at 728C for 2 min. After amplification,
15 ml of each PCR reaction were resolved on a 1·8% agarose gel
(GIBCO BRL, Life Technologies, Paisley, UK).
RESULTS
Accumulation of CD8þCD28¹ anergic subpopulations
associated with lack of proliferation and IL-2 production in
advanced HIV-1 disease
Analysis of lymphocyte subpopulations in all three patients with
advanced HIV-1, on HAART before immunotherapy, revealed
predominantly anergic CD8þCD28¹ cells with an increased
CD57þ subset (Fig. 1). This anergy was reflected in the inability
of cells to proliferate in response to all antigens tested (Fig. 2).
Occasionally, weak proliferative responses to pokeweed mitogen
(PWM) were seen. Lack of proliferation was associated with lack of
IL-2 production as well as unresponsiveness to high doses of IL-2
(100 U/ml). However, low levels of IL-4 were detected in response
to antigens to which the patients were known to have been
exposed, such as herpes simplex virus (HSV) for patient 1, and
HSV, Candida and p24 for patient 3. We further investigated in
detail the in vivo influence of IL-2 on proliferative responses in all
three patients and the influence of the combination of both IL-2 and
GM-CSF on T cell subsets and immune responses in one patient.
Immunophenotypic analysis of peripheral blood from patient 3
before and after IL-2 immunotherapy is shown in Tables 2 and 3.
Lack of both proliferation and IL-2 production to HIV-1 recom-
binant antigens (p24 and gp120), mitogens and recall antigens was
accompanied by the presence of measurable levels of IL-4 in tissue
culture supernatant, approximately 1 U/ml, when cells were stimu-
lated with p24, HSV and purified C. albicans antigens (Table 1).
Up-regulated expression, in both percentage and mean fluores-
cence intensity, of IL-4-modulated markers CD23, CD40, CD80
and CD86 in comparison with control cells (Table 3), further
substantiated the presence of IL-4 in the system.
Administration of IL-2 increased NK activity, induced HIV-1
peptide-specific IFN-g-secreting CD8þ T cells which paralleled
loss of IL-4
In all three patients after administrations of IL-2 there was no
significant effect on CD4 counts and there was no improvement in
proliferative responses to mitogens, recall or HIV-1 antigens.
Three weeks after the first course of IL-2 in patient 3, flow
cytometric analysis revealed a two-fold increase in total lympho-
cyte numbers, yet again barely detectable levels of CD4þ cells in
peripheral blood (Table 2). Although overall numbers of CD3þ and
CD8þ subsets almost doubled, their percentage of total lympho-
cytes decreased (Table 2). This decrease in the percentage of CD8þ
subpopulation was associated with increase in the CD3¹CD16þ
NK cell subset (Table 2). This was accompanied by increased NK
cell killing from 31% before IL-2 therapy to 59% after IL-2 therapy
(Fig. 3a). Upon administration of IL-2 there was a decrease in the
percentage of CD45RAþ whole PBMC subset and a further
dramatic increase in CD95 expression (Table 3). Reduction in
the ab TCR subset was noted, whilst CD57 expression increased
(Table 2). There were no significant changes in the expression of
either gd TCR or CD28þ subsets. There was, however, a significant
decrease in CD38, CD23, CD40, CD80 and CD86 expression on
total PBMC (Table 3). Despite the decrease of these molecules and
loss of IL-4 in culture supernatants after IL-2 immunotherapy
(Table 1), no apparent proliferation or IL-2 production were
initially seen in response to mitogens, recall and HIV-1 recom-
binant antigens (Table 1). However, a three-fold increase in IFN-g-
secreting cells upon stimulation with PHA was seen (Fig. 3b).
Measurement of HLA-B35-restricted HIV-1 peptide-specific IFN-
g-secreting cells revealed a significant increase in the activity of
these cells following IL-2 immunotherapy (Fig. 3c). No IFN-g-
secreting cells were seen in negative cultures (cells only or
irrelevant peptides) or by HLA-B35 uninfected control cells
(low numbers of HLA-B35-restricted Epstein–Barr virus (EBV)
peptide-specific IFN-g SFC were seen).
Administration of IL-2 and GM-CSF restores proliferative
responses to both HIV-1 and recall antigen, IL-2 production and
responsiveness to IL-2
Following subsequent administrations of IL-2 and GM-CSF in
patient 3, a partial restoration of proliferative responses to PHA
and PWM was seen together with very strong proliferative
responses to p24 and C. albicans (Table 1). All proliferative
responses were associated with IL-2 production, whereas no IL-4
was detected in cultures (Table 1). Additionally, when PBMC were
challenged with 100 U/ml of IL-2, a strong IL-2-induced response
was seen (Table 1). Analyses of the kinetics of cytokine (IL-2, IL-4
and IL-10) mRNA expression by RT-PCR revealed up-regulated
expression of IL-2 message at day 3 upon stimulation with p24
(lane 7, upper panel, Fig. 4) at days 1 and 3 upon stimulation with
Candida antigen (lanes 9 and 11, upper panel, Fig. 4), and at days 2 and
3 in response to IL-2 (lanes 14 and 15, upper panel, Fig. 4). No IL-4- or
IL-10-specific mRNA expression was detected in response to any of the
three stimuli (middle and lower panel, respectively, Fig. 4).
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Fig. 1. Two-colour flow cytometric analysis of the expression of CD28 and
CD57 molecules on the predominant CD8þ lymphocytes (> 90% CD8þ)
reveals accumulation of the CD8þCD28¹CD57þ anergic subset in
advanced HIV-1 disease. Expression was assessed by direct immuno-
fluorescence, using the FITC-conjugated anti-CD28 and PE-conjugated
anti-CD57 MoAbs. A representative result is shown.
Patients experienced mild fevers, rigors and night sweats
during and immediately subsequent to immunotherapy. After
three cycles of immunotherapy patient 3 experienced clinical
improvement with increased weight, reduced fevers and night
sweats, and cessation of his abdominal pain. Computed tomo-
graphy scan of the abdomen demonstrated a reduction in para-
aortic lymphadenopathy, and endoscopy showed a reduction in
MAC load on duodenal biopsy. Blood cultures were negative for
culture of MAC. Importantly, throughout the period of cytokine
administration the patients’ viral load remained below the detection
limit.
DISCUSSION
IL-2 has been used clinically in short-term randomized compar-
isons using continuous i.v. therapy at varying doses and more
recently in studies using anti-retroviral agents in combination with
subcutaneous IL-2 administration [21,22]. These studies have
shown a considerable expansion of the CD4þ subpopulation,
mainly in those individuals with CD4 counts > 200 at the time
therapy was initiated. In this study, we have described the impact
of potent HAART with immunomodulators on the host immune
response in patients with very advanced HIV-1 disease, one of
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Fig. 2. Absence of proliferative responses to recombinant HIV-1 antigens, recall antigens, mitogens and IL-2 in patients with advanced HIV-1
disease on highly active anti-retroviral therapy (HAART) (upper panel). Peripheral blood mononuclear cells (PBMC) were incubated with the
indicated stimuli for 6 days and 3H-thymidine incorporation was measured. Proliferation of uninfected control cells is shown for comparison
(results from a representative control are shown; lower panel).
them presenting with a severe opportunistic infection. In all three
patients where HAART alone had a modest effect on CD4þ T cell
counts, although viral loads were undetectable, we observed
accumulation of anergic lymphocyte subsets which failed to
proliferate in response to mitogen, recall or HIV-1 recombinant
antigen. For patient 3, the patient’s condition was complicated by
MAC, which remained unresponsive to conventional treatment.
Detailed immunovirological analyses revealed that before IL-2
therapy, 97% of lymphocytes were CD3þ (73% ab and 8·5% gd),
with low levels of CD4þ cells (4%) and the majority (88%) being
CD8þCD28¹ cells, of which 20% were CD57þ. In culture, these
cells appeared microscopically non-dividing but healthy, suggest-
ing anergy. These observations are consistent with other reports,
describing an atypical phenotype of CD8þCD28¹CD57þ anergic
cells in HIV-1-infected individuals [10–12]. Analysis of CD1a
expression showed no presence of immature thymocytes. Increased
levels of CD95 and CD38 expression were noted compared with
controls. Surprisingly, upon administration of IL-2 there was a
further increase in CD95 (Fas) expression. Increased expression of
CD95 might indicate that cells have the potential to apoptose. Fas,
however, needs to be cross-linked and the presence of FasL is
required [23,24]. Increased Fas expression upon activation per se
suggests that cells are activated but are not necessarily committed
to apoptosis. No DNA fragmentation was seen (data not shown),
but this was not surprising since the CD8þCD28¹ subpopulation
has been shown to contain high levels of the anti-apoptotic Bcl-2,
to have shortened telomeres and to have low clonogenic potential
[12,25]. Additionally, increased levels of CD38, leading to the
CD38–CD38L interaction, may provide rescue signals from pro-
grammed cell death [12,26]. More CD45RAþ (naive) cells were
seen before IL-2 treatment, although lower levels of both naive and
effector/memory (CD45ROþ) were observed in comparison with
those seen for the uninfected control. Reduction in the percentage
of CD45RAþ subpopulation in PBMC upon IL-2 therapy suggests
an altered pattern of migration, such as enhanced entry into lymph
nodes.
The expansion of the CD4 compartment in all three patients
was very limited after IL-2 immunotherapy. In patient 3, whilst
both CD3þ and CD8þ cells increased numerically, their propor-
tions were reduced by 14% and 18%, respectively, owing to the
over 10-fold increase in the CD3¹CD16þCD57þ NK cell numbers,
reflected in an 8% rise in their proportion of the total lymphocyte
population. This increase was reflected in the two-fold increase of
NK cell-mediated cytotoxicity. Before and after the initial
immunotherapy cells from all three patients failed to proliferate
or produce IL-2 when challenged with HIV-1 recombinant anti-
gens, mitogens or recall antigens. When pretherapy PBMC from
patients 1 and 3 were stimulated with HSV; or with p24, HSV, or
C. albicans, respectively, there was a lack of proliferation and IL-2
production. However secretion of IL-4 was detected in response to
these specific antigens. Since patient 1 had recurrent genital HSV
and patient 3 previously had oesophageal candidiasis and recurrent
genital HSV, this IL-4 production is most likely to be antigen-
specific. This was associated with up-regulated expression of
CD23, CD40, CD80 and CD86, which are known to be induced
by IL-4 and expressed by activated T cells [27–29]. Increased
expression of these molecules before treatment may indicate the
existence of an immunosuppressive microenvironment within
these patients. Generation of the anti-p24, anti-HSV, and anti-
Candida-specific responses within a microenvironment, rich in IL-4
and with T cells lacking costimulatory capacity, is most likely to
lead to immunosuppression rather than activation and proliferation
(IL-2 production). This concurs with the hypothesis that a type-2
cytokine environment may have a profound anti-proliferative
effect [8]. Loss of IL-4 upon immunotherapy, mirrored by increase
in IFN-g release in response to mitogen as well as increases in both
the HIV-1 peptide-specific IFN-g-secreting cells and the NK cell-
mediated cytotoxicity, suggests a shift from type-2 towards a type-
1 response. IL-2 immunotherapy increased the number of CD8þ
cells and CD3¹CD16þCD57þ NK cells in the blood of patient 3,
either by induction and/or clonal expansion or by changes in the
migration pathways of these cells. This led to significantly higher
levels of IFN-g-producing, HIV-1 peptide-specific T cells (likely
to be CD8þ cytotoxic T cells) in the blood. Because of the
increased expression of CD95, these cells are probably the result
of clonal expansion. However, they did not appear to express
CD45RO, as there was no dramatic increase in the number of ROþ
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Table 2. Lymphocyte population and subpopulations by flow cytometry
Cells/ml (% cells stained)
Population/ Before IL-2 After IL-2
subpopulation immunotherapy immunotherapy
Total lymphocytes 1476 3160
CD3 (T cells) 1433 (97) 2634 (83)
CD4 56 (4) 79 (3)
CD8 1296 (88) 2204 (70)
CD19 (B cells) 55 (4) 63 (2)
CD16þ CD3¹ (NK cells) 29 (2·9) 348 (11)
ab TCR (T cell receptor) 73% 62%
gd TCR 8·5% 10·5%
CD28 9·8% 8·7%
CD57 21·5% 30%
Table 3. Single-colour flow cytometric analysis of naive/resting
(CD45RAþ) and memory/effector (CD45ROþ) cell subpopulations,
immature thymocytes, activation markers and IL-4-influenced/induced
molecules
Percent cells stained (mean fluorescence intensity)
Uninfected Before IL-2 After IL-2
Subpopulation* control immunotherapy immunotherapy
CD45RA (naive) 30·28 (181·14) 16·1 (30·82) 6·9 (7·5)
CD45RO (memory) 23·65 (160·63) 7·1 (30·45) 6·03 (8·22)
CD1a (thymocytes) 4·7 (57·80) 5·5 (29·48) 3·05 (4·94)
CD38 (activation) 7·9 (36·34) 14·12 (52·44) 4·3 (11·52)
CD95 (Fas)† 4·6 (39·16) 14·45 (59·55) 42·5 (18·14)
HLA-DR (class II) 7·7 (41·34) 7·2 (43·18) 5·6 (11·47)
CD23 (FceRII)‡ 1·6 (25·28) 9·6 (41·73) 8·23 (14·68)
CD40 (costim.) 2·02 (12·25) 10·6 (52·01) 4·3 (15·29)
CD80 (B7.1)‡ 1·01 (7·23) 5·5 (33·44) 2·4 (6·32)
CD86 (B7.2)‡ 7·9 (36·34) 14·1 (52·44) 4·3 (11·52)
*Isotype-matched controls were < 2% (12·00).
†Need FasL for apoptosis.
‡Also expressed on activated T cells.
Representative of three replica experiments is shown.
cells after IL-2 immunotherapy. This may be attributed to the
fact that recently activated cells lose CD45RA and do not express
RO until several days later [30]. The immunological changes
observed are consistent with what is already known about the
role of IL-2 in vitro, and from previous in vivo studies [31–33]. A
considerable expansion of the NK cell subset was noted with a
relative diminution of the type-2 IL-4-producing cells. Impor-
tantly, following IL-2 infusion more type-1-like cells producing
IFN-g were seen.
Since IL-2 immunotherapy did not result in major clinical
improvements and in view of its inability to suppress symptomatic
MAC infection, GM-CSF was co-administered with further IL-2.
GM-CSF, produced by both type-1 and type-2 cytokine-secreting
cells, is a cytokine with a broad spectrum of cell-differentiating
and colony-stimulating activities [34,35]. The combination of GM-
CSF and IL-2 injections appeared more effective in inducing both
HIV-1-specific and non-specific proliferative responses, associated
with IL-2 production and up-regulated IL-2-specific mRNA
expression. In addition, restoration of responsiveness to IL-2 was
seen, suggesting that up-regulation of IL-2/IL-2R interactions/
signalling is essential to the ability of these cells to respond to
antigenic stimuli. Moreover, neither IL-4- nor IL-10-specific
mRNA expression was detected in response to p24, Candida or
IL-2, indicating that administration of IL-2 and GM-CSF together
does not induce the anti-proliferative type-2 responses. Of con-
siderable importance was reappearance of anti-HIV-1 proliferative
responses, which had not been seen before in advanced HIV-1
disease, raising the possibility that a combination of both IL-2 and
GM-CSF may have a beneficial effect on the treatment of advanced
HIV-1 disease. These considerable improvements in immunologi-
cal function were associated with clinical improvement in the
patients’ ability to control MAC infection. Patients experienced
mild side-effects during and immediately subsequent to immuno-
therapy. Utilization of cytokines to enhance and steer immune
responses to HIV-1 antigens towards a desired phenotype has
become an area of enormous interest [35]. Our data raise the
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Fig. 3. IL-2 increases natural killer (NK) activity and induces non-specific and HIV-1 peptide-specific IFN-g-secreting cells. (a) Measurement
of the NK-mediated cytotoxicity by patient’s NK cells before (X) and after (B) IL-2 immunotherapy, and by uninfected controls (open
symbols); s.d. of the mean for each effector cell dilution was < 5%. (b) ELISPOT assay measuring IFN-g release in response to
phytohaemagglutinin (PHA) by peripheral blood mononuclear cells (PBMC) obtained before and after IL-2 immunotherapy. The data
represent average values at each point and variation among duplicates was < 10%. (c) ELISPOT assays measuring IFN-g release in response to
HLA-B35-restricted peptides. Patient cells obtained before and after IL-2 immunotherapy, and HLA-B35 uninfected donor cells were
stimulated with or without HLA-B35-restricted peptides: (i) HIV-RT: HPDIVIYQY; (ii) HIV-p17: NSSKVSQNY; (iii) Flu-M: ASCMGLIY;
(iv) EBV-EBNA3A: YPLHEQHGM. Patient 3 HLA phenotype: A1/24, B35/61, Bw6 C4/1202 DR4/7 DRB4-53 DQB0601; uninfected donor
HLA phenotype: A11/33 B7/35 Bw6 C4/1202 DR1/1303 DRB3-52 DRB4-53 DQ5/7.
possibility that, in late-stage HIV-1 disease, IL-2 and GM-CSF
immunotherapy as a supplement to HAART may restore important
immune responses, namely priming of CD4þ cells and subsequently
CD8þ cell function as well as antigen presentation. These responses
are considered to play an important role in remission of clinically
persistent opportunistic disease and control of HIV-1 replication.
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